Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth

Cancer Research

Volumn 71, Issue 22, 2011, Pages 6965-6975

  Schmid, Michael C ^a   Avraamides, Christie J ^a   Foubert, Philippe ^a   Shaked, Yuval ^c,d   Kang, Sang Won ^e   Kerbel, Robert S ^d   Varner, Judith A ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; COMBRETASTATIN A1 PHOSPHATE; ELN 476063; GEMCITABINE; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; PAXILLIN; PLERIXAFOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TALIN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CELL ADHESION; CONTROLLED STUDY; DRUG INHIBITION; ENZYME INHIBITION; FEMALE; GRANULOCYTE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LUNG CARCINOMA; MACROPHAGE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD11B; CELL MOVEMENT; CHEMOKINE CXCL12; INFLAMMATION; INTEGRIN ALPHA4BETA1; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASMS; PAXILLIN; TALIN;

EID: 81155126053     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0588     Document Type: Article

References (38)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7. (Pubitemid 36019639)
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
3. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21. (Pubitemid 39361441)
4. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006;66:11238-46. (Pubitemid 46009952)
5. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, et al. Macrophages promote the invasion of breast carcinoma cells via a colony-stimulating factor-1/epidermal growth factor paracrine loop. Cancer Res 2005;65: 5278-83. (Pubitemid 40827339)
6. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, et al. Proliferating macrophages associated with high-grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat 2011;128:703-11.
7. Oosterling SJ, van der Bij GJ, Meijer GA, Tuk CW, van Garderen E, van Rooijen N, et al. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol 2005;207:147-55. (Pubitemid 41404145)
8. Du R, Petritsch C, Liu P, Ganss R, Passegué E, Song H, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206-20. (Pubitemid 351318372)
9. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008;13:193-205. (Pubitemid 351318369)
10. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995;72:818-23.
11. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, et al. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42. (Pubitemid 34919050)
12. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009;182:4499-506.
13. Nagaraj S, Gabrilovich DI. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res 2008;68:2561-3. (Pubitemid 351556251)
14. Terabe M, Matsui S, Park JM, Mamura M, Noben-Trauth N, Donaldson DD, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T-lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003;198:1741-52.
15. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008;180:2011-7.
16. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000;6:3282-9. (Pubitemid 30637758)
17. Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313:1785-7. (Pubitemid 44454154)
18. Jin H, Aiyer A, Su J, Borgstrom P, Stupack D, Friedlander M, et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J Clin Invest 2006;116:652-62. (Pubitemid 43326874)
19. Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res 2006;66:2146-52.
20. Arnaout MA, Mahalingam B, Xiong JP. Integrin structure, allostery, and bidirectional signaling. Annu Rev Cell Dev Biol 2005;21:381-410. (Pubitemid 41740640)
21. Luque A, Gómez M, Puzon W, Takada Y, Sánchez-Madrid F, Caba~nas C. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355- 425) of the common beta 1 chain. J Biol Chem 1996;271:11067-75. (Pubitemid 26155933)
22. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003;163:2113-26. (Pubitemid 37310040)
23. Feral CC, Rose DM, Han J, Fox N, Silverman GJ, Kaushansky K, et al. Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest 2006;116:715-23. (Pubitemid 43326880)
24. Schmid MC, Avraamides CJ, Dippold HC, Franco I, Foubert P, Ellies LG, et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011;19;715-27.
25. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R. Chemokines direct endothelial progenitors into tumor neovessels. Proc Natl Acad Sci U S A 2005;102:18111-6. (Pubitemid 41798510)
26. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007;67:10019-26. (Pubitemid 47621253)
27. Rose DM, Han J, Ginsberg MH. Alpha4 integrins and the immune response. Immunol Rev 2002;186:118-24.
28. Grabovsky V, Feigelson S, Chen C, Bleijs DA, Peled A, Cinamon G, et al. Subsecond induction of alpha4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J Exp Med 2000;192:495-506.
29. Alon R, Feigelson SW, Manevich E, Rose DM, Schmitz J, Overby DR, et al. Alpha4beta1-dependent adhesion strengthening under mechanical strain is regulated by paxillin association with the alpha4-cytoplasmic domain. J Cell Biol 2005;171:1073-84. (Pubitemid 41815838)
30. Ferrara N. Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol 2010;17:219-24.
31. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007;25:911-20. (Pubitemid 47236916)
32. Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008;14:263-73.
33. Furusato B, Mohamed A, Uhlen M, Rhim JS. CXCR4 and cancer. Pathol Int 2010;60:497-505.
34. Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 2006;25:387-408. (Pubitemid 44922357)
35. Naldini A, Filippi I, Miglietta D, Moschetta M, Giavazzi R, Carraro F. Interleukin-1β regulates the migratory potential of MDAMB231 breast cancer cells through the hypoxia-inducible factor-1α. Eur J Cancer 2010;46:3400-8.
36. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 2010;11:1133-46.
37. Voronov E, Reich E, Dotan S, Dransh P, Cohen I, Huszar M, et al. Effects of IL-1 molecules on growth patterns of 3-MCA-induced cell lines: an interplay between immunogenicity and invasive potential. J Immunotoxicol 2010;7:27-38.
38. Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol Rev 2008;222:222-41. (Pubitemid 351430377)